BIOCRYST director receives stock grant as chair retainer

MILANO VINCENT reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

MILANO VINCENT reported acquisition or exercise transactions in this Form 4 filing.

BIOCRYST PHARMACEUTICALS INC director Vincent Milano reported receiving 1,122 shares of Common Stock on May 29, 2026. These shares were granted as compensation, issued in lieu of 50% of his quarterly cash Board Chair retainer of $20,000. After this grant, he directly holds 93,189 shares of the company’s common stock. This is a routine, non-market award rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 1,122 shares

Grant/Award 1 txn

Insider MILANO VINCENT

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,122	$8.91	$10K

Holdings After Transaction: Common Stock — 93,189 shares (Direct)

Footnotes (1)

1. F1. Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $20,000.

Key Figures

Shares granted: 1,122 shares Grant price: $8.91 per share Shares held after grant: 93,189 shares +1 more

4 metrics

Shares granted 1,122 shares Common Stock grant on May 29, 2026

Grant price $8.91 per share Value reference for compensation grant

Shares held after grant 93,189 shares Direct holdings following May 29, 2026 transaction

Quarterly Board Chair retainer portion $20,000 50% paid in stock instead of cash

Key Terms

Common Stock, grant, award, or other acquisition, Board Chair retainer

3 terms

Common Stock financial

"Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Board Chair retainer financial

"in lieu of 50% of the quarterly cash Board Chair retainer of $20,000"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BIOCRYST (BCRX) report for Vincent Milano?

Vincent Milano received 1,122 BIOCRYST Common Stock shares on May 29, 2026 as a grant. The award was issued as part of his Board Chair compensation, not an open-market stock purchase.

Was the BCRX Form 4 transaction a stock purchase or a compensation grant?

The Form 4 shows a compensation grant, not a market purchase. Milano received 1,122 shares coded as an “A” transaction, representing a grant or award tied to his Board Chair retainer.

How is Vincent Milano’s Board Chair retainer paid at BIOCRYST (BCRX)?

Half of Milano’s quarterly Board Chair retainer of $20,000 is paid in stock rather than cash. The May 29, 2026 Form 4 records shares issued in lieu of that 50% cash portion.

How many BIOCRYST (BCRX) shares does Vincent Milano hold after this Form 4?

Following the May 29, 2026 stock grant, Vincent Milano directly holds 93,189 shares of BIOCRYST Common Stock. This figure reflects his position after adding the 1,122-share Board Chair compensation award.

What does transaction code “A” mean in the BCRX Form 4 for Vincent Milano?

Transaction code “A” indicates a grant, award, or other acquisition of shares. For Milano, it reflects a stock grant received as part of his Board Chair retainer, not an open-market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILANO VINCENT

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		A		1,122(1)	A	$8.91	93,189	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $20,000.

	/s/ Alane P. Barnes, by power of attorney	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)